The American Society of Clinical Oncology (ASCO) just released draft recommendations on medical therapy for stage I–III breast cancer for public comment, specifically regarding adjuvant chemotherapy and adjuvant targeted therapy.
Click here to review the draft recommendations for Medical Therapy for Stage I–III HR+, HER2-Negative Breast Cancer Guideline – Adjuvant Chemotherapy and Adjuvant Targeted Therapy, after agreeing to a confidentiality agreement.
The comment window closes on October 27, 2025.
Sign up for alerts to keep up with the latest clinical guidelines and guideline updates.
Copyright © 2025 Guideline Central, all rights reserved.